Abstract
Neural plasticity refers to the capability of the brain to modify its structure and/or function and organization in response to a changing environment. Evidence shows that disruption of neuronal plasticity and altered functional connectivity between distinct brain networks contribute significantly to the pathophysiological mechanisms of schizophrenia. Transcranial magnetic stimulation has emerged as a noninvasive brain stimulation tool that can be utilized to investigate cortical excitability with the aim of probing neural plasticity mechanisms. In particular, in pathological disorders, such as schizophrenia, cortical dysfunction, such as an aberrant excitatory-inhibitory balance in cortical networks, altered cortical connectivity, and impairment of critical period timing are very important to be studied using different TMS paradigms. Studying such neurophysiological characteristics and plastic changes would help in elucidating different aspects of the pathophysiological mechanisms underlying schizophrenia. This review attempts to summarize the findings of available TMS studies with diagnostic and characterization aims, but not with therapeutic purposes, in schizophrenia. Findings provide further evidence of aberrant excitatory-inhibitory balance in cortical networks, mediated by neurotransmitter pathways such as the glutamate and GABA systems. Future studies with combining techniques, for instance, TMS with brain imaging or molecular genetic typing, would shed light on the characteristics and predictors of schizophrenia.
Highlights
Schizophrenia is a complex chronic mental health disorder characterized by a positive and negative array of symptoms [1]
First- and second-generation antipsychotics are the first line of treatment for schizophrenia [5]
We searched for studies published in the following electronic databases including the Cochrane Library, PubMed, EMBASE, and Web of Science, using the search terms as follows: e.g., “Schizophrenia” AND “transcranial magnetic stimulation “or “psychiatric Disorders” AND “Transcranial magnetic stimulation (TMS)” or “schizophrenia” AND “brain plasticity Index” or paired pulse stimulation, from inception to September, 2021
Summary
Schizophrenia is a complex chronic mental health disorder characterized by a positive and negative array of symptoms [1]. Diagnosis of schizophrenia is incomplete unless one of the positive symptoms is present: hallucinations, delusions, and disorganized speech or behaviors [2]. Despite numerous research in neuroimaging, epidemiology, and genetics, treatment of schizophrenia is still not optimal, and its exact etiologic factors remain elusive. Researchers are attempting to be more specific in treating only a single psychotic symptom [3, 4]. First- and second-generation antipsychotics are the first line of treatment for schizophrenia [5]. The schizophrenia prognosis offers poor outcomes despite current treatment; patients often remain symptomatic, and 25%-33% of patients are treatmentresistant [6]. Antipsychotics are associated with significant side effects, leading to additional complications in treating the disease [7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.